LONDON – A growing body of in vitro, animal and more recently, clinical research is pointing to the potential for tyrosine kinase inhibitors (TKIs), which have established their therapeutic value in cancer, to be repurposed as treatments for Alzheimer's and other neurodegenerative diseases. Read More
